Format

Send to

Choose Destination
Br J Haematol. 2019 Apr 2. doi: 10.1111/bjh.15898. [Epub ahead of print]

Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome.

Author information

1
Department of Haematology, Kobe City Hospital Organization Kobe City Medical Centre General Hospital, Kobe, Japan.
2
Centre for Community-based Healthcare Research and Education, Shimane University, Izumo, Japan.
3
Department of Haematology, Kanagawa Cancer Centre, Yokohama, Japan.
4
Haematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan.
5
Leukaemia Research Centre, Saiseikai Maebashi Hospital, Gunma, Japan.
6
Department of Haematopoietic Stem Cell Transplantation, National Cancer Centre Hospital, Tokyo, Japan.
7
Department of Haematology, Shinshu University School of Medicine, Nagano, Japan.
8
Department of Haematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
9
Division of Haematology, Jichi Medical University Saitama Medical Centre, Saitama, Japan.
10
Division of Haematology and Stem Cell Transplantation, Shizuoka Cancer Centre, Shizuoka, Japan.
11
Department of Haematology, Hamanomachi Hospital, Fukuoka, Japan.
12
Department of Haematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
13
Department of Haematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
14
Japanese Data Centre for Haematopoietic Cell Transplantation, Aichi, Japan.
15
Department of Haematology, Kanazawa University Hospital, Kanazawa, Japan.

Abstract

Though second allogenic haematopoietic stem cell transplantation (HSCT) is considered a curative treatment option after myelodysplastic syndrome (MDS) relapse, scant epidemiological data are available. We investigated the outcomes and prognostic factors of second allogenic HSCT in 99 patients with MDS who relapsed after the first HSCT. The median age was 53 years (interquartile; 45-59) and 57 patients (57·6%) were male. Five-year overall survival was 25·3%. Early relapse (adjusted hazard ratio: 2·78, 95% confidence interval: 1·08-7·21, P = 0·035) and poor performance (3·03, 1·71-5·37, P < 0·001) were associated with a significantly poor 5-year overall survival compared to the other groups (P < 0·001).

KEYWORDS:

allogeneic haematopoietic stem cell transplantation; early relapse; myelodysplastic syndrome; performance status; second allogeneic haematopoietic stem cell transplantation

PMID:
30941758
DOI:
10.1111/bjh.15898

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center